Alyeska Investment Group L.P. Has $381,000 Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL)

Alyeska Investment Group L.P. trimmed its stake in Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) by 43.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the company's stock after selling 76,382 shares during the period. Alyeska Investment Group L.P. owned about 1.30% of Precision BioSciences worth $381,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of Precision BioSciences by 40.7% in the third quarter. Geode Capital Management LLC now owns 65,974 shares of the company's stock valued at $591,000 after buying an additional 19,088 shares during the period. Samalin Investment Counsel LLC bought a new position in Precision BioSciences during the fourth quarter worth $59,000. Commonwealth Equity Services LLC acquired a new stake in Precision BioSciences during the 4th quarter worth about $48,000. Moloney Securities Asset Management LLC raised its position in shares of Precision BioSciences by 177.0% in the 4th quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company's stock worth $335,000 after acquiring an additional 56,100 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Precision BioSciences by 36.2% in the 4th quarter. Renaissance Technologies LLC now owns 109,798 shares of the company's stock valued at $418,000 after purchasing an additional 29,200 shares during the period. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Stock Up 1.7%

NASDAQ:DTIL traded up $0.09 during trading hours on Monday, reaching $5.22. The company had a trading volume of 22,876 shares, compared to its average volume of 182,597. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $13.44. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The firm has a market cap of $55.02 million, a price-to-earnings ratio of 86.91 and a beta of 1.55. The business's 50-day simple moving average is $5.03 and its two-hundred day simple moving average is $5.57.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing the consensus estimate of ($2.09) by ($1.11). The firm had revenue of $3.47 million during the quarter, compared to analyst estimates of $4.28 million. Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. On average, equities analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Precision BioSciences in a research note on Friday, March 28th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.